Enlivex Therapeutics Files 6-K with Q3 Financials
Ticker: ENLV · Form: 6-K · Filed: Nov 29, 2024 · CIK: 1596812
Sentiment: neutral
Topics: financials, sec-filing, quarterly-report
Related Tickers: ENLV
TL;DR
ENLV dropped Q3 financials in a 6-K, check it out.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on November 29, 2024, reporting its unaudited condensed consolidated financial statements for the three and nine month periods ended September 30, 2024. The company, previously known as Bioblast Pharma Ltd., is incorporated in Israel and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with the latest financial performance data for Enlivex Therapeutics, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not introduce new risks.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Bioblast Pharma Ltd. (company) — Former company name
- November 29, 2024 (date) — Filing date
- September 30, 2024 (date) — Financial reporting period end date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the unaudited condensed consolidated financial statements for the three and nine month periods ended September 30, 2024.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on November 29, 2024.
What was Enlivex Therapeutics Ltd. formerly known as?
Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd.
Under which country's laws is Enlivex Therapeutics Ltd. organized?
Enlivex Therapeutics Ltd. is organized under the laws of the State of Israel.
What is the SIC code for Enlivex Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Enlivex Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 310 words · 1 min read · ~1 pages · Grade level 10 · Accepted 2024-11-29 16:30:04
Filing Documents
- ea0222802-6k_enlivex.htm (6-K) — 12KB
- ea022280201ex99-1_enlivex.htm (EX-99.1) — 318KB
- ea022280201ex99-2_enlivex.htm (EX-99.2) — 96KB
- 0001213900-24-104120.txt ( ) — 426KB
Financial Statements
Financial Statements The unaudited condensed consolidated financial statements for Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“ Enlivex ”), as of and for the three and nine month periods ended September 30, 2024 and 2023 , and the Operating and Financial Review and Prospects of Enlivex for the corresponding periods are furnished as Exhibits 99.1 and 99.2, respectively, to this Report on Form 6-K and incorporated by reference into Enlivex’s registration statements on Forms S-8, F-3 and F-3MEF (File No. 333-256799 , File No. 333-232413 , File No. 333-232009 , File No. 333-252926 and File No. 333-264561 ) , filed with the Securities and Exchange Commission. Exhibit No. 99.1 Unaudited condensed consolidated financial statements for Enlivex as of September 30, 2024 and December 31, 2023 and for the three and nine month periods ended September 30, 2024 and 2023. 99.2 Operating and Financial Review and Prospects as of and for the three and nine month periods ended September 30, 2024 and 2023. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: November 29, 2024 2